Regeneron Pharma (REGN) PT Raised to $400 at Barclays Following 1Q Report; 'Initial Strength of the Dupixent Launch'
Tweet Send to a Friend
Barclays raised its price target on Regeneron Pharma (NASDAQ: REGN) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
